Naciri Bennani H.Banza A.T.Terrec F.Noble J.Jouve T.Motte L.Malvezzi P.Rostaing L.Mahidol University2023-06-182023-06-182023-02-01Therapeutic Apheresis and Dialysis Vol.27 No.1 (2023) , 159-16917449979https://repository.li.mahidol.ac.th/handle/20.500.14594/85135Background: Cryoglobulinemia is defined as the presence of an abnormal immunoglobulin that may be responsible for vasculitis of small-caliber vessels. Apheresis can be used in order to temporarily eliminate circulating cryoglobulins. The aim of this study was to assess the effectiveness of apheresis (double-filtration plasmapheresis-DFPP-) in symptomatic and/or severe cryoglobulinemias. Methods: Four male patients presenting cryoglobulinemic vasculitis and who received DFPP sessions were included. Results: Their mean age was 57 ± 15 years. One patient had hepatitis-C virus (HCV)-related cryoglobulinemia and the other three patients were carriers of an IgM Kappa monoclonal gammopathy. Mean duration of follow-up was 15 ± 2 months. DFPP allowed healing of ulcerative skin lesions in the first patient and remission of nephrotic syndrome in the other patients after a median of 6(5–10) sessions. Conclusion: DFPP can be used safely in cryoglobulinemic-vasculitis and can be considered early to achieve a faster and sustained clinical-biological response.MedicineArticleSCOPUS10.1111/1744-9987.138852-s2.0-851307137681744998735583180